10º Foro de Inmunologia Traslacional en Inmmunoterapia del cáncer

22 FIT Cancer 10 10 th FORUM ON Translational Immunology and IMMUNOTHERAPY OF CANCER CP-24. EFFECT OF THE HLA-G/ILT2 PATHWAY AS AN IMMUNE SYSTEM CHECKPOINT IN GASTRIC CANCER Christian Vaquero-Yuste1; Óscar Aguilar-Sopeña1; Inmaculada Lasa2; Adela López2; Remedios Gómez2; Alberto Gutiérrez-Calvo2; Pedro Roda-Navarro1,3; José Manuel Martin-Villa1,4; Ignacio Juárez1 1Department of Immunology, Ophthalmology, and Otorhinolaryngology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain. 2Department of General and Digestive Surgery, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain. 3Lymphocyte Immunobiology Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain. 4Department of Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain CP-26. ASSOCIATION OF PDE4D AND STK11 AS BIOMARKERS OF THE RESPONSE TO IMMUNOTHERAPY IN NOT SMALL CELLS LUNG CARCINOMA (NSCLC) Laura Boyero1; María G. Velasco-Domínguez1; Sofía Boyero-Corral1; José Francisco NogueraUclés1; Miriam Alonso2; Amparo Sánchez-Gastaldo2; Johana Cristina Benedetti2; Sonia MolinaPinelo1; Reyes Bernabé Caro2 1 Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain. 2Hospital Universitario Virgen del Rocío, Sevilla, Spain CP-27. IMPACT OF CYCLIN INHIBITORS (CDK4/6I) ON IMMUNE CELL POPULATIONS IN FIRST-LINE TREATED METASTATIC BREAST CANCER PATIENTS María Luisa Sánchez León; Carlos Jiménez Cortegana; Fernando Henao Carrasco; Natalia Palazón Carrión; Silvia Silva Romeiro; Víctor Sánchez Margalet; Luis de la Cruz Merino Hospital Universitario Virgen Macarena, Sevilla, Spain CP-28. OVERCOMING IMMUNOTHERAPY RESISTANCE: THE INVERSION OF THE NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A PREDICTIVE KEY TO TREATMENT SUCCESS Lucas Sanz Monge1; Javier Plou Izquierdo2; Javier Garrido Gallego1; Tomás Cunquero Tomás3; Alfonso Berrocal Jaime1 1Hospital General Universitario de Valencia, Valencia, Spain. 2CIC nanoGUNE, Donostia, Guipuzkoa, Spain. 3Hospital General de Requena, Requena, Valencia CP-29. CD8+ NKS AS A POTENTIAL BIOMARKER OF COMPLETE RESPONSE AND SURVIVAL WITH LENALIDOMIDE PLUS R-GDP IN THE R2-GDP-GOTEL TRIAL IN RECURRENT/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA Lourdes Hontecillas Prieto1; Daniel J. García-Domínguez2; Víctor Sánchez-Margalet2; Luis de la Cruz-Merino3 1Clinical Biochemistry Service, Hospital Universitario Virgen Macarena, Universidad de Sevilla, Sevilla, Spain. 2Department of Medical Biochemistry and Molecular Biology and Immunology, School of Medicine, Hospital Universitario Virgen Macarena, Universidad de Sevilla, Sevilla, Spain. 3Hospital Universitario Virgen Macarena, Sevilla, Spain

RkJQdWJsaXNoZXIy MTQzMjMwMg==